<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04014153</url>
  </required_header>
  <id_info>
    <org_study_id>1/13</org_study_id>
    <nct_id>NCT04014153</nct_id>
  </id_info>
  <brief_title>CI-AKI in Patients With Stable CAD and Comorbidities. Are we Doing Better?</brief_title>
  <official_title>The Impact of Comorbidity as a Risk Factor of Acute Kidney Injury (AKI) in Patients With Stable Coronary Artery Disease (CAD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>I.M. Sechenov First Moscow State Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>I.M. Sechenov First Moscow State Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients aged 18-89 with stable CAD and comorbidities receiving optimal medical treatment
      requiring PCI with iodinated contrast media.

      The aim of the study is to assess the prevalence of contrast-induced AKI in 2012-2013 and
      2017 cohorts and to evaluate the potential risk factors of CI-AKI to better guide the
      prevention in patients of higher risk.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 16, 2012</start_date>
  <completion_date type="Actual">December 12, 2018</completion_date>
  <primary_completion_date type="Actual">October 19, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Overall mortality</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cardiovascular mortality</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Myocardial infarction</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Stroke</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>GI bleeding</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>CABG</measure>
    <time_frame>5 years</time_frame>
    <description>CABG after PCI at enrolment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PCI</measure>
    <time_frame>5 years</time_frame>
    <description>Repeat PCI after the enrolment</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">1023</enrollment>
  <condition>Stable Angina</condition>
  <condition>Acute Kidney Injury</condition>
  <condition>Contrast-induced Nephropathy</condition>
  <arm_group>
    <arm_group_label>Group 1 (5-year prognosis)</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 (1-year prognosis)</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Iodinated contrast media</intervention_name>
    <description>Percutaneous coronary intervention with iodinated contest media</description>
    <arm_group_label>Group 1 (5-year prognosis)</arm_group_label>
    <arm_group_label>Group 2 (1-year prognosis)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Both genders suffering from stable coronary artery disease, requiring percutaneous coronary
        intervention with intra-arterial iodinated contrast injection
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed consent

          -  Male and female patients 18 y. o. and older

          -  Verified stable coronary artery disease (CAD)

          -  Receiving optimal medical treatment and requiring percutaneous coronary intervention
             (PCI) with iodinated contrast media

        Exclusion Criteria:

          -  Pregnancy, lactation

          -  Conditions affecting the prognosis (kidney failure, liver failure, oncology)

          -  Acute coronary syndrome (ACS)

          -  Stroke

          -  Contraindications to PCI

          -  Therapy with nephrotoxic drugs during the enrolment which cannot be stopped

          -  Refusal to sign the informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>89 Years</maximum_age>
  </eligibility>
  <reference>
    <citation>Mironova OIu. [Contrast substances-induced nephropathy]. Ter Arkh. 2013;85(6):90-5. Review. Russian.</citation>
    <PMID>23875199</PMID>
  </reference>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>July 7, 2019</study_first_submitted>
  <study_first_submitted_qc>July 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 10, 2019</study_first_posted>
  <last_update_submitted>October 25, 2019</last_update_submitted>
  <last_update_submitted_qc>October 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>I.M. Sechenov First Moscow State Medical University</investigator_affiliation>
    <investigator_full_name>Olga Mironova</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>acute kidney injury</keyword>
  <keyword>coronary artery disease</keyword>
  <keyword>contrast-induced acute kidney injury</keyword>
  <keyword>comorbidity</keyword>
  <keyword>CI-AKI</keyword>
  <keyword>stable CAD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Kidney Injury</mesh_term>
    <mesh_term>Angina, Stable</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

